Royal Bank of Canada
UTHR icon

Royal Bank of Canada’s United Therapeutics UTHR Stock Holding History

Royal Bank of Canada’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-100
Closed -$9K – 6141
2014
Q1 		$9K Sell
100
-100
-50% -$10.2K ﹤0.01% 5464
2013
Q4 		$23K Buy
200
+100
+100% +$9.02K ﹤0.01% 5202
2013
Q3 		$8K Buy
+100
New +$7.31K ﹤0.01% 5494

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Royal Bank of Canada's UTHR Position: Q2 2026 in Review

Royal Bank of Canada increased its United Therapeutics (UTHR) stake by 5.8% in Q2 2026, buying an estimated $1.94M and bringing the position to 62,600 shares worth $33.9M. The position accounts for 0.01% of the portfolio, ranked #1228.

Royal Bank of Canada first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $35.1M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Royal Bank of Canada held 62,600 shares of United Therapeutics worth $33.9M as of Q2 2026.
  • Royal Bank of Canada bought 3,448 United Therapeutics shares in Q2 2026, an estimated $1.94M.
  • United Therapeutics made up 0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #1228 holding.
  • Royal Bank of Canada first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Royal Bank of Canada's United Therapeutics position peaked at $35.1M in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.